ABSTRACT
Aggregation of the ß-Amyloid (Aß) peptide in brain tissues is the hallmark of Alzheimer's disease (AD). While Aß is presumed to be insidiously involved in the disease's pathophysiology, concrete mechanisms accounting for the role of Aß in AD are yet to be deciphered. While Aß has been primarily identified in the extracellular space, the peptide also accumulates in cellular compartments such as mitochondria and lysosomes and impairs cellular functions. Here, we show that prominent proapoptotic peptides associated with the mitochondrial outer membrane, the Bcl-2-homology-only peptides BID, PUMA, and NOXA, exert significant and divergent effects upon aggregation, cytotoxicity, and membrane interactions of Aß42, the main Aß homolog. Interestingly, we show that BID and PUMA accelerated aggregation of Aß42, reduced Aß42-induced toxicity and mitochondrial disfunction, and inhibited Aß42-membrane interactions. In contrast, NOXA exhibited opposite effects, reducing Aß42 fibril formation, affecting more pronounced apoptotic effects and mitochondrial disfunction, and enhancing membrane interactions of Aß42. The effects of BID, PUMA, and NOXA upon the Aß42 structure and toxicity may be linked to its biological properties and affect pathophysiological features of AD.
Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Amyloid beta-Peptides/toxicity , Humans , Mitochondria , Peptide FragmentsABSTRACT
A review of the multidisciplinary scientific literature reveals a large variety of amyloid-ß (Aß) oligomeric species, differing in molecular weight, conformation and morphology. These species, which may assemble via either on- or off-aggregation pathways, exhibit differences in stability, function and neurotoxicity, according to different experimental settings. The conformations of the different Aß species are stabilized by intra- and inter-molecular hydrogen bonds and by electrostatic and hydrophobic interactions, all depending on the chemical and physical environment (e.g., solvent, ions, pH) and interactions with other molecules, such as lipids and proteins. This complexity and the lack of a complete understanding of the relationship between the different Aß species and their toxicity is currently dictating the nature of the inhibitor (or inducer)-based approaches that are under development for interfering with (or inducing) the formation of specific species and Aß oligomerization, and for interfering with the associated downstream neurotoxic effects. Here, we review the principles that underlie the involvement of different Aß oligomeric species in neurodegeneration, both in vitro and in preclinical studies. In addition, we provide an overview of the existing inhibitors (or inducers) of Aß oligomerization that serve as potential therapeutics for neurodegenerative diseases. The review, which covers the exciting studies that have been published in the past few years, comprises three main parts: 1) on- and off-fibrillar assembly mechanisms and Aß structural polymorphism; 2) interactions of Aß with other molecules and cell components that dictate the Aß aggregation pathway; and 3) targeting the on-fibrillar Aß assembly pathway as a therapeutic approach.
Subject(s)
Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/metabolism , Amyloid/chemistry , Neurodegenerative Diseases/pathology , Peptide Fragments/metabolism , Humans , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/therapy , Peptide Fragments/genetics , Protein Aggregation, Pathological/pathology , Protein ConformationABSTRACT
It is currently believed that molecular agents that specifically bind to and neutralize the toxic proteins/peptides, amyloid ß (Aß42), tau, and the tau-derived peptide PHF6, hold the key to attenuating the progression of Alzheimer's disease (AD). We thus tested our previously developed nonaggregating Aß42 double mutant (Aß42DM) as a multispecific binder for three AD-associated molecules, wild-type Aß42, the tauK174Q mutant, and a synthetic PHF6 peptide. Aß42DM acted as a functional inhibitor of these molecules in in vitro assays and in neuronal cell-based models of AD. The double mutant bound both cytotoxic tauK174Q and synthetic PHF6 and protected neuronal cells from the accumulation of tau in cell lysates and mitochondria. Aß42DM also reduced toxic intracellular levels of calcium and the overall cell toxicity induced by overexpressed tau, synthetic PHF6, Aß42, or a combination of PHF6and Aß42. Aß42DM inhibited PHF6-induced overall mitochondrial dysfunction: In particular, Aß42DM inhibited PHF6-induced damage to submitochondrial particles (SMPs) and suppressed PHF6-induced elevation of the ζ-potential of inverted SMPs (proxy for the inner mitochondrial membrane, IMM). PHF6 reduced the lipid fluidity of cardiolipin/DOPC vesicles (that mimic the IMM) but not DOPC (which mimics the outer mitochondrial membrane), and this effect was inhibited by Aß42DM. This inhibition may be explained by the conformational changes in PHF6 induced by Aß42DM in solution and in membrane mimetics. On this basis, the paper presents a mechanistic explanation for the inhibitory activity of Aß42DM against Aß42- and tau-induced membrane permeability and cell toxicity and provides confirmatory evidence for its protective function in neuronal cells.
Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Amyloid beta-Peptides/toxicity , Humans , Membranes, Artificial , Mitochondria , Peptide Fragments/toxicity , tau ProteinsABSTRACT
BIM is a key apoptotic protein, participating in diverse cellular processes. Interestingly, recent studies have hypothesized that BIM is associated with the extensive neuronal cell death encountered in protein misfolding diseases, such as Alzheimer's disease. Here, we report that the core pro-apoptotic domain of BIM, the BIM-BH3 motif, forms ubiquitous amyloid fibrils. The BIM-BH3 fibrils exhibit cytotoxicity, disrupt mitochondrial functions, and modulate the structures and dynamics of mitochondrial membrane mimics. Interestingly, a slightly longer peptide in which BIM-BH3 was flanked by four additional residues, widely employed as a model of the pro-apoptotic core domain of BIM, did not form fibrils, nor exhibited cell disruptive properties. The experimental data suggest a new mechanistic role for the BIM-BH3 domain, and demonstrate, for the first time, that an apoptotic peptide forms toxic amyloid fibrils.
Subject(s)
Amyloid/chemistry , Apoptosis , Bcl-2-Like Protein 11/chemistry , Protein Domains , Amino Acid Sequence , Amyloid/metabolism , Amyloid/ultrastructure , Bcl-2-Like Protein 11/genetics , Bcl-2-Like Protein 11/metabolism , Cell Line, Tumor , Cell Survival , Circular Dichroism , Electron Transport Complex IV/metabolism , Humans , Microscopy, Electron , Mitochondria/metabolism , Mitochondria/ultrastructure , Mitochondrial Proteins/metabolism , Reactive Oxygen Species/metabolism , Sequence Homology, Amino AcidABSTRACT
Destabilization of plasma and inner mitochondrial membranes by extra- and intracellular amyloid ß peptide (Aß42) aggregates may lead to dysregulated calcium flux through the plasma membrane, mitochondrial-mediated apoptosis, and neuronal cell death in patients with Alzheimer's disease. In the current study, experiments performed with artificial membranes, isolated mitochondria, and neuronal cells allowed us to understand the mechanism by which a nonaggregating Aß42 double mutant (designated Aß42DM) exerts its neuroprotective effects. Specifically, we showed that Aß42DM protected neuronal cells from Aß42-induced accumulation of toxic intracellular levels of calcium and from apoptosis. Aß42DM also inhibited Aß42-induced mitochondrial membrane potential depolarization in the cells and abolished the Aß42-mediated decrease in cytochrome c oxidase activity in purified mitochondrial particles. These results can be explained in terms of the amelioration by Aß42DM of Aß42-mediated changes in membrane fluidity in DOPC and cardiolipin/DOPC phospholipid vesicles, mimicking plasma and mitochondrial membranes, respectively. These observations are also in agreement with the inhibition by Aß42DM of phospholipid-induced conformational changes in Aß42 and with the fact that, unlike Aß42, the Aß42-Aß42DM complex could not permeate into cells but instead remained attached to the cell membrane. Although most of the Aß42DM molecules were localized on the cell membrane, some penetrated into the cytosol in an Aß42-independent process, and, unlike Aß42, did not form intracellular inclusion bodies. Overall, we provide a mechanistic explanation for the inhibitory activity of Aß42DM against Aß42-induced membrane permeability and cell toxicity and provide confirmatory evidence for its protective function in neuronal cells.
Subject(s)
Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/pharmacology , Membranes, Artificial , Mitochondrial Membranes/drug effects , Neuroprotective Agents/pharmacology , Peptide Fragments/genetics , Peptide Fragments/pharmacology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Apoptosis/drug effects , Calcium/metabolism , Humans , Mitochondrial Membranes/metabolism , Neurons/drug effects , Peptide Fragments/metabolismABSTRACT
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by selective death of motor neurons in the brainstem, motor cortex, and spinal cord, leading to muscle atrophy and eventually to death. It is currently held that various oligomerization-inducing mutations in superoxide dismutase 1 (SOD1), an amyloid-forming protein, may be implicated in the familial form of this fast-progressing highly lethal neurodegenerative disease. A possible therapeutic approach could therefore lie in developing inhibitors to SOD1 mutants. By screening a focused mutagenesis library, mutated randomly in specific "stability patch" positions of the B1 domain of protein G (HTB1), we previously identified low affinity inhibitors of aggregation of SOD1G93A and SOD1G85R mutants. Herein, with the aim to generate a more potent inhibitor with higher affinity to SOD1 mutants, we employed an unbiased, random mutagenesis approach covering the entire sequence space of HTB1 to optimize as yet undefined positions for improved interactions with SOD1. Using affinity maturation screens in yeast, we identified a variant, which we designated HTB1M3 , that bound strongly to SOD1 misfolded mutants but not to wild-type SOD1. In-vitro aggregation assays indicated that in the presence of HTB1M3 misfolded SOD1 assembled into oligomeric species that were not toxic to NSC-34 neuronal cells. In addition, when NSC-34 cells were exposed to misfolded SOD1 mutants, either soluble or preaggregated, in the presence of HTB1M3 , this inhibitor prevented the prion-like propagation of SOD1 from one neuronal cell to another by blocking the penetration of SOD1 into the neuronal cells.
Subject(s)
Neurodegenerative Diseases/metabolism , Superoxide Dismutase-1/chemistry , Superoxide Dismutase-1/metabolism , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Animals , Cell Line , Cell Survival/genetics , Cell Survival/physiology , Flow Cytometry , Humans , Mice , Mutation , Neurodegenerative Diseases/genetics , Neurons/metabolism , Protein Folding , Superoxide Dismutase-1/geneticsABSTRACT
Intra- and extraneuronal deposition of amyloid ß (Aß) peptides have been linked to Alzheimer's disease (AD). While both intra- and extraneuronal Aß deposits affect neuronal cell viability, the molecular mechanism by which these Aß structures, especially when intraneuronal, do so is still not entirely understood. This makes the development of inhibitors challenging. To prevent the formation of toxic Aß structural assemblies so as to prevent neuronal cell death associated with AD, we used a combination of computational and combinatorial-directed evolution approaches to develop a variant of the HTB1 protein (HTB1M2). HTB1M2 inhibits in vitro self-assembly of Aß42 peptide and shifts the Aß42 aggregation pathway to the formation of oligomers that are nontoxic to neuroblastoma SH-SY5Y cells overexpressing or treated with Aß42 peptide. This makes HTB1M2 a potential therapeutic lead in the development of AD-targeted drugs and a tool for elucidating conformational changes in the Aß42 peptide.
Subject(s)
Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/toxicity , Extracellular Fluid/metabolism , Genetic Engineering/methods , Intracellular Fluid/metabolism , Peptide Fragments/metabolism , Peptide Fragments/toxicity , Protein Aggregates/physiology , Amyloid beta-Peptides/genetics , Cell Line, Tumor , Extracellular Fluid/drug effects , Humans , Intracellular Fluid/drug effects , Peptide Fragments/genetics , Protein Aggregates/drug effects , Protein Domains/drug effects , Protein Domains/physiology , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolismABSTRACT
Aggregation and accumulation of the 42-residue amyloid ß peptide (Aß42) in the extracellular matrix and within neuronal cells is considered a major cause of neuronal cell cytotoxicity and death in Alzheimer's disease (AD) patients. Therefore, molecules that bind to Aß42 and prevent its aggregation are therapeutically promising as AD treatment. Here, we show that a non-self-aggregating Aß42 variant carrying two surface mutations, F19S and L34P (Aß42DM), inhibits wild-type Aß42 aggregation and significantly reduces Aß42-mediated cell cytotoxicity. In addition, Aß42DM inhibits the uptake and internalization of extracellularly added pre-formed Aß42 aggregates into cells. This was the case in both neuronal and non-neuronal cells co-expressing Aß42 and Aß42DM or following pre-treatment of cells with extracellular soluble forms of the two peptides, even at high Aß42 to Aß42DM molar ratios. In cells, Aß42DM associates with Aß42, while in vitro, the two soluble recombinant peptides exhibit nano-molar binding affinity. Importantly, Aß42DM potently suppresses Aß42 amyloid aggregation in vitro, as demonstrated by thioflavin T fluorescence and transmission electron microscopy for detecting amyloid fibrils. Overall, we present a new approach for inhibiting Aß42 fibril formation both within and outside cells. Accordingly, Aß42DM should be evaluated in vivo for potential use as a therapeutic lead for treating AD.
Subject(s)
Amyloid beta-Peptides/metabolism , Amyloid/metabolism , Extracellular Fluid/metabolism , Genetic Variation/physiology , Intracellular Fluid/metabolism , Peptide Fragments/metabolism , Protein Aggregation, Pathological/metabolism , Amyloid/genetics , Amyloid beta-Peptides/genetics , Cell Line, Tumor , Cell Survival/physiology , HEK293 Cells , Humans , Peptide Fragments/genetics , Protein Aggregation, Pathological/genetics , Surface Plasmon Resonance/methodsABSTRACT
Molecular agents that specifically bind and neutralize misfolded and toxic superoxide dismutase 1 (SOD1) mutant proteins may find application in attenuating the disease progression of familial amyotrophic lateral sclerosis. However, high structural similarities between the wild-type and mutant SOD1 proteins limit the utility of this approach. Here we addressed this challenge by converting a promiscuous natural human IgG-binding domain, the hyperthermophilic variant of protein G (HTB1), into a highly specific aggregation inhibitor (designated HTB1M) of two familial amyotrophic lateral sclerosis-linked SOD1 mutants, SOD1G93A and SOD1G85R We utilized a computational algorithm for mapping protein surfaces predisposed to HTB1 intermolecular interactions to construct a focused HTB1 library, complemented with an experimental platform based on yeast surface display for affinity and specificity screening. HTB1M displayed high binding specificity toward SOD1 mutants, inhibited their amyloid aggregation in vitro, prevented the accumulation of misfolded proteins in living cells, and reduced the cytotoxicity of SOD1G93A expressed in motor neuron-like cells. Competition assays and molecular docking simulations suggested that HTB1M binds to SOD1 via both its α-helical and ß-sheet domains at the native dimer interface that becomes exposed upon mutated SOD1 misfolding and monomerization. Our results demonstrate the utility of computational mapping of the protein-protein interaction potential for designing focused protein libraries to be used in directed evolution. They also provide new insight into the mechanism of conversion of broad-spectrum immunoglobulin-binding proteins, such as HTB1, into target-specific proteins, thereby paving the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in a variety of human diseases.